Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

@article{An2015ActivationOP,
  title={Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.},
  author={Ningfei An and Ying Xiong and Amanda C. Larue and Andrew S. Kraft and Bo Cen},
  journal={Cancer research},
  year={2015},
  volume={75 24},
  pages={
          5318-28
        }
}
Mesenchymal-epithelial transition (MET) blockade offers a new targeted therapy particularly in those cancers with MET amplification. However, the efficacy and the duration of the response to MET inhibitors are limited by the emergence of drug resistance. Here, we report that resistance to small-molecule inhibitors of MET can arise from increased expression of the prosurvival Pim protein kinases. This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with… 

Figures from this paper

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.
TLDR
A potential role of PIM inhibition inMET amplified tumors and of SRC inhibition in MET addicted tumors is identified and potential applications of this new treatment strategy warrant further evaluation.
Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway
TLDR
It is demonstrated that resistance to small molecule AKTprotein kinase inhibitors is potentially mediated by the Pim-1 protein kinase, and that unique Pim protein kinases that can in turn synergize with AKT inhibitors to block prostate cancer growth overcome this resistance.
Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer
TLDR
This review focuses on the signaling pathways through which PIM kinases promote cancer progression and resistance to therapy, as well as highlights biological contexts and promising strategies to exploit PIM as a therapeutic target in cancer.
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
TLDR
PIM controls NAD(P)H production by increasing glucose flux through the pentose phosphate shunt decreasing ROS production, and thereby diminishing the cytotoxicity of PI3K-AKT inhibitors.
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
TLDR
A review of the current challenges and future opportunities for HGF/MET targeting for therapeutic cancer interventions is summarized and simultaneously proposed.
A review on PIM kinases in tumors
TLDR
As Pim-1 possesses oncogenic functions and is over expressed in various kinds of cancer diseases, its inhibition provides a new option in cancer therapy and designing new inhibitors of PIMs is now a very active area of research in academic and industrial laboratories.
Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer
TLDR
A generalizable resistance mechanism to TKIs is defined and inhibition of B cl-2 and Bcl-xL is rationalized as a strategy to augment responses and blunt acquired resistance to TkIs in lung and gastric cancer.
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
TLDR
This review discusses the role and setting for use of selective MET inhibitors, mainly focusing on selective MET tyrosine kinase inhibitors (TKIs), in the treatment of NSCLC with MET exon 14 skipping mutations.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
TLDR
This is the first report showing that overexpression of wt KRAS can overcome the inhibitory effect of a RTK inhibitor, and the results provide insights into strategies for preventing and/or overcoming drug resistance.
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.
TLDR
The results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
TLDR
Therapies that combine MET inhibitors capable of inhibiting Y1230 mutant MET in combination with anti-EGFR-based therapies may enhance clinical benefit for patients with MET-addicted cancers and highlight the daunting challenges associated with preventing or overcoming resistance.
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
TLDR
Findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance.
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
TLDR
It is shown that gastric cancer cells with high-level stable chromosomal amplification of the growth factor receptor MET are extraordinarily susceptible to the selective inhibitor PHA-665752, which may identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway.
Pim-1 plays a pivotal role in hypoxia-induced chemoresistance
TLDR
It is demonstrated that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance, and targeting PIM-1 may improve the chemotherapeutic strategy for solid tumors.
The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling
TLDR
A previously unrecognized mechanism that promotes MET expression in multiple tumor cell types is described and it is found that Pim-1 kinase activity regulates HGF-induced tumor cell migration, invasion, and cell scattering.
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
TLDR
The results strongly suggest that Met amplification identifies a subset of NSCLC likely to respond to new molecular therapies targeting Met, which is implicated in growth, invasion, and metastasis of many tumors includingNSCLC.
...
...